Tag
Despite proven benefits, medications for alcohol use disorder remain underprescribed at hospital discharge. This study identifies hospitalization and patient factors influencing new prescriptions, highlighting opportunities to enhance AUD t
Nearly half of psychoactive medications newly prescribed after ICU stays in American adults lack documented diagnostic justification, persisting for up to two years post-hospitalization.
A large claims-based study reveals pembrolizumab dominates immunotherapy prescribing for head and neck cancer, with minimal usage growth since FDA approval. Immune-related adverse events occurred in 41.2% of patients, linked to specific com
A new study reveals that neurologists receiving $1,000 or more from drug manufacturers were over 4 times more likely to prescribe expensive brand-name MS medications when generics were available, driving up costs for patients and the health
Pharmaceutical companies have significantly increased marketing payments to clinicians for ADHD medications, particularly targeting advanced practice clinicians. The impact of this trend on prescribing patterns and clinical benefits remains
